Pretreated EGFR/BRAF Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

O J Corrado,Federico Cappuzzo,Landi Lorenza, Resuli Blerina,Carpano Silvia, Vicente Sperb Antonello,Buglioni Simonetta, María‐Dolores Chiara,Ciliberto Gennaro, Madonna Gabriele

JTO Clinical and Research Reports（2023）

引用 0|浏览4

暂无评分

摘要

Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.

查看译文

关键词

leptomeningeal disease achieving,egfr/braf lung adenocarcinoma,osimertinib,dabrafenib,long-lasting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要